Acarix Revenue and Competitors

Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.